Immunotherapy by autologous dendritic cell vaccine in patients with advanced HCC.

Background: Dendritic cells (DCs) could be used as potential cellular adjuvant for the production of specific tumor vaccines.

Objectives: Our study was aimed to evaluate the safety and efficacy of autologous pulsed DC vaccine in advanced hepatocellular carcinoma (HCC) patients in comparison with supportive treatment.

Methods: Thirty patients with advanced HCC not suitable for radical or loco-regional therapies were enrolled.